Cargando…

A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherin

Accumulation of genetic and epigenetic changes contributes to cancer development and progression. Compared with gene mutations or deletions, epigenetic changes are reversible, which alter the chromatin structure remodeling instead of changes in DNA sequence, and therefore become a promising strategy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Li-Ting, Liou, Jing-Ping, Li, Yu-Hsuan, Liu, Yi-Min, Pan, Shiow-Lin, Teng, Che-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170623/ https://www.ncbi.nlm.nih.gov/pubmed/25015091

Ejemplares similares

Anticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells
por: Tsai, Feng-Lung, et al.
Publicado: (2023)

Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
por: Chao, Min-Wu, et al.
Publicado: (2019)

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells
por: Chen, M-C, et al.
Publicado: (2013)

MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells
por: Huang, Fang-I, et al.
Publicado: (2019)

The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
por: Tu, Huang-Ju, et al.
Publicado: (2018)

A Novel Dual HDAC6 and Tubulin Inhibitor, MPT0B451, Displays Anti-tumor Ability in Human Cancer Cells in Vitro and in Vivo
por: Wu, Yi-Wen, et al.
Publicado: (2018)

A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo
por: Wu, Yi-Wen, et al.
Publicado: (2021)

MPT0G612, a Novel HDAC6 Inhibitor, Induces Apoptosis and Suppresses IFN-γ-Induced Programmed Death-Ligand 1 in Human Colorectal Carcinoma Cells
por: Chen, Mei-Chuan, et al.
Publicado: (2019)

Specific Control of Pancreatic Endocrine β- and δ-Cell Mass by Class IIa Histone Deacetylases HDAC4, HDAC5, and HDAC9
por: Lenoir, Olivia, et al.
Publicado: (2011)

Class I HDACs specifically regulate E‐cadherin expression in human renal epithelial cells
por: Choi, Sin Y., et al.
Publicado: (2016)

E-Cadherin-Deficient Epithelial Cells Are Sensitive to HDAC Inhibitors
por: Decourtye-Espiard, Lyvianne, et al.
Publicado: (2021)

Class IIa HDACs in myelination
por: Velasco-Aviles, Sergio, et al.
Publicado: (2018)

Changes in Class I and IIb HDACs by δ-Opioid in Chronic Rat Glaucoma Model
por: Zaidi, Syed A. H., et al.
Publicado: (2020)

Correction: Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo
por: Huang, Han-Li, et al.
Publicado: (2012)

Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo
por: Huang, Han-Li, et al.
Publicado: (2014)

Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo
por: Huang, Han-Lin, et al.
Publicado: (2012)

aPKC Phosphorylation of HDAC6 Results in Increased Deacetylation Activity
por: Du, Yifeng, et al.
Publicado: (2015)

Regulating the Regulators: The Post-Translational Code of Class I HDAC1 and HDAC2
por: Segré, Chiara V., et al.
Publicado: (2011)

Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma
por: Chen, Mei-Chuan, et al.
Publicado: (2015)

E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors
por: Jordaan, Gwen, et al.
Publicado: (2013)

HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer
por: Lin, Ching-Ling, et al.
Publicado: (2019)

MPT0G066, a novel anti-mitotic drug, induces JNK-independent mitotic arrest, JNK-mediated apoptosis, and potentiates antineoplastic effect of cisplatin in ovarian cancer
por: Huang, Han-Li, et al.
Publicado: (2016)

A novel action mechanism for MPT0G013, a derivative of arylsulfonamide, inhibits tumor angiogenesis through up-regulation of TIMP3 expression
por: Wang, Chih-Ya, et al.
Publicado: (2014)

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014)

Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma
por: Huang, Renhong, et al.
Publicado: (2018)

Recent Update of HDAC Inhibitors in Lymphoma
por: Chen, I-Chung, et al.
Publicado: (2020)

Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines
por: Sixto-López, Yudibeth, et al.
Publicado: (2020)

Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis
por: Li, Song, et al.
Publicado: (2011)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
por: Thomas, Elizabeth A.
Publicado: (2014)

Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes
por: Nebbioso, Angela, et al.
Publicado: (2009)

Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells
por: Liu, Jiaqi, et al.
Publicado: (2016)

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
por: Yoon, Somy, et al.
Publicado: (2016)

Hydroxyl Ketone-Based Histone Deacetylase Inhibitors To Gain Insight into Class I HDAC Selectivity versus That of HDAC6
por: Traoré, Mohamed D. M., et al.
Publicado: (2017)

HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer
por: Mayr, Christian, et al.
Publicado: (2021)

Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
por: Schäker‐Hübner, Linda, et al.
Publicado: (2022)

An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells
por: Chao, Min-Wu, et al.
Publicado: (2017)

MPT0B098, a Microtubule Inhibitor, Suppresses JAK2/STAT3 Signaling Pathway through Modulation of SOCS3 Stability in Oral Squamous Cell Carcinoma
por: Peng, Hsuan-Yu, et al.
Publicado: (2016)

Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
por: Luo, Yuxiang, et al.
Publicado: (2020)

HDAC3 and HDAC8 are required for cilia assembly and elongation
por: Park, Seon-ah, et al.
Publicado: (2019)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
por: King, Jacob, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eulsj42vk4rb5s0k9n0acjo3ev